.

Make Better Decisions

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Citi
Teva
Merck
Colorcon
Harvard Business School
Cerilliant
US Army
Healthtrust
Farmers Insurance
Cantor Fitzgerald

Generated: February 24, 2018

DrugPatentWatch Database Preview

US Patents With Foreign Priority to United Kingdom Patent: 0305681.9

« Back to Dashboard


Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Astrazeneca PharmsLYNPARZAolaparibCAPSULE;ORAL206162-001Dec 19, 2014RXYesYes➤ Try a Free Trial➤ Try a Free TrialYY
Astrazeneca PharmsLYNPARZAolaparibTABLET;ORAL208558-001Aug 17, 2017RXYesNo➤ Try a Free Trial➤ Try a Free TrialYY
Astrazeneca PharmsLYNPARZAolaparibTABLET;ORAL208558-002Aug 17, 2017RXYesYes➤ Try a Free Trial➤ Try a Free TrialYY
Astrazeneca PharmsLYNPARZAolaparibCAPSULE;ORAL206162-001Dec 19, 2014RXYesYes➤ Try a Free Trial➤ Try a Free TrialTREATMENT OF BRCA MUTATED OVARIAN CANCER USING PARP INHIBITOR
Astrazeneca PharmsLYNPARZAolaparibTABLET;ORAL208558-001Aug 17, 2017RXYesNo➤ Try a Free Trial➤ Try a Free TrialMAINTENANCE TREATMENT OF RECURRENT EPITHELIAL OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCER, WHO ARE IN A COMPLETE OR PARTIAL RESPONSE TO PLATINUM-BASED CHEMOTHERAPY
Astrazeneca PharmsLYNPARZAolaparibTABLET;ORAL208558-001Aug 17, 2017RXYesNo➤ Try a Free Trial➤ Try a Free TrialTREATMENT OF DELETERIOUS OR SUSPECTED DELETERIOUS GERMLINE BRCA-MUTATED ADVANCED OVARIAN CANCER WHO HAVE BEEN TREATED WITH THREE OR MORE PRIOR LINES OF CHEMOTHERAPY BASED ON AN FDA-APPROVED COMPANION DIAGNOSTIC FOR LYNPARZA
Astrazeneca PharmsLYNPARZAolaparibTABLET;ORAL208558-002Aug 17, 2017RXYesYes➤ Try a Free Trial➤ Try a Free TrialMAINTENANCE TREATMENT OF RECURRENT EPITHELIAL OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCER, WHO ARE IN A COMPLETE OR PARTIAL RESPONSE TO PLATINUM-BASED CHEMOTHERAPY
Astrazeneca PharmsLYNPARZAolaparibTABLET;ORAL208558-002Aug 17, 2017RXYesYes➤ Try a Free Trial➤ Try a Free TrialTREATMENT OF DELETERIOUS OR SUSPECTED DELETERIOUS GERMLINE BRCA-MUTATED ADVANCED OVARIAN CANCER WHO HAVE BEEN TREATED WITH THREE OR MORE PRIOR LINES OF CHEMOTHERAPY BASED ON AN FDA-APPROVED COMPANION DIAGNOSTIC FOR LYNPARZA
This preview shows a limited number of results
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Table 'thinkbio_newdpw.patent_gazette' doesn't exist